GSK closes sale of thrombosis brands to Aspen
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline has completed the £700m sale of two thrombosis brands to South Africa's largest listed pharma company, Aspen. The previously announced deal (scripintelligence.com, 30 September 2013) closed following regulatory approval of the transaction. The majority of commercial operations will formally transfer to Aspen on 1 January 2014 with the remainder, as well as the Notre-Dame de Bondeville manufacturing site, transferring in mid-2014.The brands in question are Arixtra (fondaparinux) and Fraxiparine (nadroparin), which booked combined sales of £177m in the first half of 2013.